TG Therapeutics (TGTX) Tops Q2 EPS by 9c

TG Therapeutics (NASDAQ: TGTX) reported Q2 EPS of $0.04, $0.09 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $73.47 million versus the consensus estimate of $65.89 million.

For earnings history and earnings-related data on TG Therapeutics (TGTX) click here.

You May Also Be Interested In

• Trump: Walmart will be lowering prices
• Goldman Sachs Downgrades Ferguson Plc. (FERG) to Neutral, 'We now see better opportunities elsewhere in our coverage'
• Lockheed Martin wins $203M in defense contracts from U.S.